The FDA approval for sparsentan in treating IgA nephropathy is a significant milestone, likely to boost Travere's market presence and revenue. Although there are setbacks in FSGS trials, the ongoing studies and FDA's involvement indicate potential future success. Financially, the company's strategy to extend its cash runway to 2028 through restructuring and secondary offerings is crucial for its sustainability.